Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720264 · ClinicalTrials.gov registry record · Phase 2
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
A Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin, sponsored by Sherif S. Far.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT01720264 is a Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin that has completed, run by Sherif S. Far. The registered enrollment target is 15 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01720264, a Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin, has completed, sponsored by Sherif S. Far.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Conditions Studied
Interventions
- DRUG Sitagliptin
Study Locations (2)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
New York
- New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720264
The ClinicalTrials.gov registry entry for NCT01720264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower). The listed sponsor is Sherif S. Far, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Sitagliptin is the first listed.
NCT01720264 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT01720264 about?
NCT01720264 is a clinical study titled "Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant". The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
What is the current status of trial NCT01720264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-11-02. Estimated completion is 2017-12-15.
What conditions does trial NCT01720264 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Lymphoma, Non-Hodgkin, Acute Lymphoid Leukemia, Leukemia, Myelogenous, Chronic, Hematopoetic Myelodysplasia.
What interventions are being tested in trial NCT01720264?
The interventions under investigation include: Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01720264?
This trial is sponsored by Sherif S. Far, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01720264 being conducted?
This trial has 2 study locations across Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.